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Alzheimer’s disease (AD) is the most common cause of dementia, and currently, there is no effective treatment. The
major neuropathological lesions in AD are accumulation of amyloid β (Aβ) as amyloid plaques and congophilic
amyloid angiopathy, as well as aggregated tau in the form of neurofibrillary tangles (NFTs). In addition, inflammation
and microglia/macrophage function play an important role in AD pathogenesis. We have hypothesized that stimulation
of the innate immune system via Toll-like receptor 9 (TLR9) agonists, such as type B CpG oligodeoxynucleotides (ODNs),
might be an effective way to ameliorate AD related pathology. We have previously shown in the Tg2576 AD model
that CpG ODN can reduce amyloid deposition and prevent cognitive deficits. In the present study, we used the
3xTg-AD mice with both Aβ and tau related pathology. The mice were divided into 2 groups treated from 7 to
20 months of age, prior to onset of pathology and from 11 to 18 months of age, when pathology is already
present. We demonstrated that immunomodulatory treatment with CpG ODN reduces both Aβ and tau pathologies,
as well as levels of toxic oligomers, in the absence of any apparent inflammatory toxicity, in both animal groups. This
pathology reduction is associated with a cognitive rescue in the 3xTg-AD mice. Our data indicate that modulation of
microglial function via TLR9 stimulation is effective at ameliorating all the cardinal AD related pathologies in an AD
mouse model suggesting such an approach would have a greater chance of achieving clinical efficacy.
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Alzheimer’s disease (AD) is the most common cause of
dementia globally [1]. AD is characterized by the pres-
ence of amyloid β (Aβ) deposits in forms of parenchymal
amyloid plaques and congophilic amyloid angiopathy
(CAA), as well as aggregated tau protein in the form of
neurofibrillary tangles (NFTs). The most toxic species of
aggregated Aβ and tau are thought to be oligomeric [2].
Inflammation is another feature of AD pathology, which
is linked to the production of cytokines by activated
microglia. Numerous studies dating to the early 1990’s
have suggested an important role for microglia in both
the formation and degradation of amyloid lesions [3,4].* Correspondence: thomas.wisniewski@nyumc.org
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article, unless otherwise stated.The importance of inflammatory pathways affecting the
function of microglia for the pathogenesis of AD is
highlighted by the results of genome-wide association
studies (GWAS), where many of the implicated genes
have a major role in immunological processes, as well as
the recent linkage to AD of a rare variant of TREM2, a
gene that regulates phagocytosis and the activation state
of microglia/macrophages [5,6]. Microglia play a critical
role in the innate immune system of the CNS and one
of the most potent ways to stimulate this system is via
the Toll-like receptors (TLRs).
The primary functions of TLRs are to recognize invad-
ing microbial pathogens, including bacteria, viruses, fungi
and protozoans, and to activate appropriate signaling path-
ways to effectively clear the threat. There are 13 distinct
TLR family members currently known in mammals, of
which the pathogen specificities of ten (TLR1-9 and 11)
have been identified [7]. We have focused on TLR9 whichtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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that contain unmethylated cytosine-guanosine (CpG)
sequences, which are commonly found in the genomes
of prokaryotes (bacteria) and viruses, while being un-
derrepresented in those of eukaryotes. Various CpG DNA
drugs that are TLR9 agonists are safe for humans and ro-
dents [8]. We hypothesized that type B CpG oligodeoxy-
nucleotides (ODNs) mediated stimulation of the innate
immune system may be an effective way to ameliorate AD
related pathology. In a prior study using the Tg2576 AD
model, which develops Aβ pathology, we have shown that
this approach can reduce amyloid deposition and prevent
cognitive deficits [9]. However, recent experience using
immunotherapeutic approaches in AD patients suggests
that for clinical benefits, it is paramount to also reduce
tau related pathology [10]. Furthermore, prior studies in
AD models have shown that some forms of TLR stimula-
tion can promote an increase in tau pathology [11-16]. In
the present study we sought to determine whether TLR9
stimulation by CpG ODNs can ameliorate not only Aβ
related pathology but also tau related pathology, while
concomitantly reducing oligomer levels in the 3xTg-AD
mouse model. We tested our approach by starting
treatment both prior to and after the onset of path-
ology. We have also conducted acute TLR9 stimulation
studies to help elucidate the mechanisms by which this
therapeutic approach can reduce AD pathology.
Materials and methods
Animals and treatment
The studies were performed in the homozygous triple
transgenic mouse model of AD (3xTg-AD) harboring
PS1M146V, APPSwe, and tauP301L transgenes [17]. These
mice develop an age-dependent and progressive neuro-
pathology that includes both amyloid plaques and
NFT- like pathology. The 3xTg-AD mice used were
bred internally at NYU School of Medicine on a 129/
C57BL6 background and were maintained on a 12 hr
light/dark cycle. All mouse care and experimental pro-
cedures were approved by the Institutional Animal
Care and Use Committee at the New York University
School of Medicine. Animals were injected intraperito-
neally (i.p.) with either the TLR9 agonist CpG ODN
1826 (2.5 mg/kg, ~63 μg) or vehicle (saline) at monthly
intervals. The mice were divided into 2 study groups
treated from 7 to 20 months of age, prior to onset of
pathology, and from 11 to 18 months of age, when
pathology is already present. There were equal numbers
of males and females in each experimental group.
Treatment and control groups included 15 mice per
group. CpG ODN 1826 [5’-TCC ATG ACG TTC CTG
ACG TT-3’ (CpG motifs in italics)], with a complete
phosphorothioate backbone, was purchased from Inte-
grated DNA Technologies. We used the same dose ofCpG ODN 1826 as in our prior study, in which we
stimulated the innate immune system in Tg2576 mice
[9]. Controls were non-Tg 129/C57BL6 mice injected
with saline on the same schedule. During the treatment
animals were closely monitored for signs of toxicity,
such as differences in total body weight, and after death
organs were examined for signs of pathology.
Behavioral testing
The mice underwent a battery of behavioral tests during
the final month of treatment. Prior to cognitive testing,
the mice were subjected to sensorimotor activity tests.
These measurements were performed to verify that any
CpG ODN treatment effects observed in the cognitive
tasks could not be confounded by differences in sensori-
motor (locomotor) abilities.
Locomotor activity
A Hamilton-Kinder Smart-Frame Photobeam System
was used to make a computerized recording of animal
activity over a designated period of time, as we have pre-
viously described [9,18,19]. Results are reported based
on distance traveled (cm), mean resting time (sec), and
velocity (average and maximum) (cm/sec).
Rotarod
The rod apparatus was used to measure forelimb and
hindlimb motor coordination and balance. The animals
were first habituated with two trials to reach a baseline
level of performance, and subsequently the mice were
tested in three trials, with 15 min intervals between
trials. In each trial, mice were placed on a 3.6 cm
diameter rod (Rotarod 7650 accelerating model; Ugo
Basile, Biological Research Apparatus, Varese, Italy)
with initial speed set at 1.5 rpm then raised every 30 s
by 0.5 rpm. A soft foam cushion was placed under the
rod to prevent injury from falling. The rod was cleaned
with water and 30% ethanol after each session. To as-
sess the performance, the speed of the rod was re-
corded when the mouse fell or inverted (by clinging)
from the top of the rotating barrel.
Radial arm maze
Spatial learning (working memory) was evaluated using
an eight-arm radial maze with a water well at the end of
each arm, as we have previously reported [9,20]. Animals
entered and exited all arms of the apparatus from a cen-
tral area which was controlled by clear guillotine doors
and operated by a remote pulley system. Prior to each
testing day, the mice were adapted to the room with
lights on for 15 min. After 4 days of adaptation, water-
restricted mice (2 hrs daily access to water) were given
one test session per day for 12 consecutive days. For
each session, all arms were baited with 0.1% saccharine
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until the eight rewards had been consumed. The number
of errors (entries to previously visited arms) and time to
complete each session were recorded. The behavioral
testing was performed by an individual blinded to the
animal’s treatment status.
Histological studies
Following behavioral testing, the mice were anesthetized
with sodium pentobarbital (150 mg/kg, i.p.) and perfused
transaortically with 0.1 M PBS, pH 7.4. The brains were
removed and the right hemisphere was immersion-fixed
in periodate-lysine paraformaldehyde (PLP), whereas the
left hemisphere was snap-frozen for biochemical ana-
lyses (measurements of Aβ levels and oligomers) and tau
protein levels (pathological and total tau). After fixation,
brains were placed in 2% DMSO/20% glycerol in PBS
and stored at 4°C until sectioned. Serial coronal brain
sections (40 μm) were cut on microtome and ten series
of sections were saved for histological and immunohisto-
chemical analysis of staining with: (1) anti-Aβ antibodies
6E10/4G8, (2) Thioflavin-S, (3) anti-GFAP antibody,
(4) anti-CD11b antibody, (5) anti-CD45 antibody, (6) anti-
CD3 antibody, (7) anti-CD206, (8) anti-Iba1, (9) anti-PHF1
antibody, (10) anti-AT8 antibody, (11) anti-MC1 antibody,
and (12) anti-HT7 antibody. Aβ deposits were stained
either with a mixture of mouse monoclonal antibodies
6E10/4G8 (total amyloid) or Thioflavin-S for fibrillar amyl-
oid (parenchymal and CAA). The following monoclonal
antibodies MC1 (conformation dependent), PHF1 (Ser396/
Ser404), AT8 (Ser202/Thr205) and HT7 (total human tau)
were used to examine tau related pathology as described
[18,21,22]. GFAP is a component of the glial intermediate
filaments that form part of the cytoskeleton in astrocytes
and is often employed as a marker of astrocytic activation.
We used four different markers to identify microglia/
macrophages: CD11b, CD45, CD206 and Iba1. CD11b
[member of β-integrin family of adhesion molecules;
also known as MAC-1 or complement receptor 3 (CR3)]
and CD45 (protein-tyrosine phosphatase) are commonly
used markers for the microglial activation at the earliest
and later stages of plaque development, respectively [23].
CD11b labels macrophages/microglia in both the M1 and
M2 activation states, while CD45 is associated with the
M1 classical activation state [24,25]. CD206 [or mannose
receptor 1 (MRC1)] is an immunohistological marker
for the M2 state of macrophage/microglia alternative
activation [24,26,27]. Iba1 (ionized calcium binding
adaptor molecule) labels all microglia, whether active
or resting, and has been used as generic microglial
marker [28,29]. The remaining series were placed in
ethylene glycol cryoprotectant (30% sucrose/30% ethyl-
ene glycol in 0.1 mol/L phosphate buffer) and stored
at −20°C.Immunohistochemistry was performed on free float-
ing sections as previously described [9]. Briefly, free-
floating sections were incubated in MOM diluents
(Vector Laboratories Inc., Burlingame, CA) containing
different mouse monoclonal primary antibodies at 4°C
overnight [anti-Aβ antibodies 6E10 and 4G8, 1:1000
(Covance Research Products Inc., Denver, PA); anti-tau
antibodies MC1, 1:100 (provided by Dr. Peter Davies);
PHF1, 1:100 (provided by Dr. Peter Davies); AT8, 1:500
(Thermo Fisher Scientific Inc., Rockford, IL); HT7,
1:2000 (Thermo Fisher Scientific Inc., Rockford, IL);
and T cell antibody CD3, 1:400 (Santa Cruz Biotechnology
Inc., Dallas, Texas)]. GFAP [rabbit polyclonal, 1:1000; 4°C
overnight (Dako Inc., Carpinteria, CA)], CD206 [rabbit
polyclonal, 1:200; 4°C overnight (Abcam Inc., Cambridge,
MA)] and Iba1 [rabbit polyclonal, 1:1000; 4°C overnight
(Wako Chemicals, Richmond, VA)] immunostaining was
performed with a primary antibody diluent composed of
0.3% Triton X-100, 0.1% sodium azide, 0.01% bacitracin,
1% bovine serum albumin (BSA), and 10% normal goat
serum in PBS, and secondary biotinylated goat anti-
rabbit antibody (Vector Laboratories Inc., Burlingame,
CA) reacted for 1 hr at 1:1000 dilution. CD45 [rat anti-
mouse, 1:1000; 4°C overnight (AbD Serotec, Raleigh,
NC)] and CD11b immunohistochemistry [rat anti-
mouse, 1:500; 4°C overnight (AbD Serotec, Raleigh,
NC)] were performed similarly to that for GFAP stain-
ing except that the secondary antibody was goat anti-
rat (Vector Laboratories Inc., Burlingame, CA) diluted
1:1000. Additionally, CD45, CD11b and CD206 staining
was also performed on a separate set of brains from
young (12 months) and aged (20 months) 3xTg-AD
mice acutely injected (12 hours before perfusion) with
CpG ODN or saline to further assess the effects of
TLR9 signaling on macrophage/microglia activation.
Double immunofluorescence for macrophage/microglia
markers (CD45 or CD206) and Aβ deposits (6E10/4G8)
or pathological tau (MC1) was done on selected sections.
Secondary antibodies were Cy3-conjugated goat anti-
mouse, Cy3-conjugated goat anti-rabbit, Alexa Fluor 488-
conjugated goat anti-rat and Alexa Fluor 488-conjugated
goat anti-rabbit [1:500; RT 2 hrs (Jackson Immuno Re-
search Laboratories Inc, West Grove PA)]. Fluorescent
imaging was performed on a Zeiss LSM 700 inverted
confocal microscope. ZEN 2011 software was used for
data collection and analyses. Perl’s Prussian blue staining
for ferric iron in hemosiderin (a degradation product of
hemoglobin) was performed on another set of sections to
detect cerebral bleeding, as described previously [30].
Equally spaced sections were mounted and stained in a so-
lution containing 10% potassium ferrocyanide and 20%
hydrochloric acid for 45 min. Fifteen Perl stained sections
were examined per mouse and the average number of iron
positive profiles per section was calculated.
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Immunostained tissue sections were quantified with a
Bioquant stereology semiautomated image analysis system
(R&M Biometrics) using a random unbiased hierarchical
sampling scheme, as published previously [9,18,31]. Fif-
teen sections were analyzed per animal. All procedures
were performed by an individual blinded to the experi-
mental study. Total Aβ burden (defined as the percentage
of test area occupied by Aβ) was quantified for the cortex
and for the hippocampus on coronal plane sections
stained with the monoclonal anti-Aβ antibodies 6E10 and
4G8. Total fibrillar Aβ burden (parenchymal and vascular)
and CAA burden (Aβ burden in the vasculature) were
evaluated separately in sections stained with Thioflavin-S,
using methods described previously [9]. The CD45 micro-
glia burden (the percentage of area in the measurement
field occupied by CD45 immunoreactive microglia) was
quantified in a manner analogous to that used to measure
the Aβ burden.Analysis of tau burden
Semiquantitative analysis of tau burden in brain sections
was based on the severity of neuronal PHF1, AT8, MC1
and HT7 immunoreactivity as described previously [18,19].
Approximately thirteen cortical and seven hippocampal
sections were analyzed per animal at 10 × magnifications.
Cortical immunolabeling was minimal. The rating was
based on the number of reactive neuronal perikarya
and processes. Immunostained sections were evaluated
on scales devised by blinded individual, which ranged
from 0 to 3 on the basis of pathology intensity.Rating of microgliosis
The assessment of the CD11b, CD206 and Iba1 immuno-
stained sections was based on a semiquantitative analysis
of the extent of microgliosis (0, a few resting microglia;
1, rare ramified and/or phagocytic microglia; 2, a few
ramified/phagocytic microglia; 3, a moderate ramified/
phagocytic microglia; 4, numerous ramified/phagocytic
microglia), as we have reported previously [9,18]. Ap-
proximately thirteen cortical and seven hippocampal
sections were analyzed per animal.Rating of astrocytosis
Reactive astrocytosis was rated on a scale of 0–4. The rat-
ing was based on a semiquantitative analysis of the extent
of GFAP immunoreactivity (number of GFAP immunore-
active cells and complexity of astrocytic branching), as we
have previously published [19,30]. Approximately thirteen
cortical and seven hippocampal sections were analyzed
per animal by an investigator who was blinded to treat-
ment group assignment.Tissue homogenization for biochemical analyses
Before extraction of Aβ and tau from brain tissue, 10%
(w/v) homogenates were prepared in tissue homogenization
buffer (20 mM Tris base, pH 7.4, 250 mM sucrose,
1 mM EDTA, 1 mM EGTA) with 100 mM phenyl-
methylsulphonyl fluoride, protease inhibitors [protease
inhibitors cocktail Complete (Roche Diagnostic GmbH,
Mannheim, Germany) plus pepstatin A (Sigma-Aldrich
Inc., St. Louis, MO)] and phosphatase inhibitors (1 mM
NaF, 1 mM Na3VO4 and 0.5 mM okadaic acid) added
immediately before homogenization, as we have previ-
ously published [18,19]. Subsequently, brain homoge-
nates were aliquoted, frozen, and stored at −80°C until
used for extraction of soluble and insoluble fractions of
both Aβ and tau, and their biochemical analyses (ELISA,
Western blot). All quantitative biochemical analyses were
performed in brain homogenate fractions of the entire left
hemisphere.
Assessment of Aβ pathology in the brain
Sandwich ELISA for Aβ levels
Tissue fractionation and extraction was performed as
previously described [9,19]. In brief, for extraction of sol-
uble Aβ, brain homogenates were thoroughly mixed with
an equal volume of 0.4% diethylamine (DEA)/100 mM
NaCl, then spun at 135 000 × g for 1 hr at 4°C, and sub-
sequently neutralized with 1/10 volume of 0.5 M Tris,
pH 6.8. Similarly for extraction of the total Aβ, homoge-
nates (200 μl) were added to 440 μl of cold formic acid
(FA) and sonicated for 1 min on ice. Subsequently,
400 μl of this solution was spun at 100,000 × g for 1 hr
at 4°C. Then, 210 μl of the resulting supernatant was di-
luted into 4 ml of FA neutralization solution (1 M Tris
base, 0.5 M Na2HPO4, 0.05% NaN3).
The total and soluble Aβ levels were measured using a
combination of mouse monoclonal antibody 6E10 (spe-
cific to an epitope present on amino acid residues 1–16
of Aβ) and two different rabbit polyclonal antibodies
specific for Aβ40 (R162) and Aβ42 (R165), in an anti-
body sandwich ELISA as described previously [9]. The
assay was performed by an investigator blinded to group
assignment.
Western blot analysis of Aβ oligomers
For Western immunoblot analysis, 10% (w/v) brain ho-
mogenates were centrifuged at 20,000 × g for 20 min at
4°C and the supernatants were transferred to clean tubes
and stored as previously described [18,30]. The total
protein concentration in the supernatant was deter-
mined using the Bicinchoninic acid assay (BCA; Pierce
Biotechnolgy, Rockford, IL). Samples (25 μg total pro-
tein), mixed with an equal volume of Tricine sample
buffer, were electrophoresed on 12.5% Tris-tricine poly-
acrylamide gels (under non-reducing conditions) and
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blocked with 5% non-fat dry milk in Tris-buffered saline
0.05% Tween 20 (TBS-T) for 2 hrs at room temperature.
Oligomer-specific A11 polyclonal antibody (Invitrogen
Corporation, Frederick, MD) was diluted (1:1000) in
0.1% BSA/TBS-T and incubated with the blots for 2 hrs
at room temperature (RT). Bound antibody was visual-
ized with horseradish peroxidase-conjugated goat anti-
rabbit IgG (1:3000; 1 h, Pierce Biotechnology, Rockford,
IL) and the ECL detection system (Pierce Biotechnology,
Rockford, IL). The specificity of A11 staining was con-
firmed by probing the membrane with anti-Aβ monoclo-
nal antibodies 6E10 or 4G8 [32]. Densitometric analysis
of A11 immunoreactive oligomer specific bands was per-
formed with NIH Image J version 1.47 software.
Sandwich ELISA for oligomeric Aβ
The levels of Aβ oligomers were determined using the
Human Aggregated Aβ ELISA kit (Invitrogen Corpor-
ation, Frederick, MD) according to the manufacturer’s
instructions and as we have previously published [18,19].
In brief, oligomeric Aβ levels in each sample were mea-
sured against a standard containing aggregated Aβ. 10%
brain homogenates (BH) were centrifuged at 100,000 × g
for 1 hr at 4°C. Samples diluted in the provided standard
diluent buffer (1:5 dilutions) were incubated for 2 hrs
at RT allowing the Aβ to bind the capture antibody
(a monoclonal antibody specific for the N-terminus of
human Aβ pre-coated to each well), followed by exten-
sive washing and incubation for 1 hr at RT with biotin
conjugated detection antibody (same as the capture
antibody) which binds to the immobilized aggregated
Aβ. After removal of excess antibody, horseradish
peroxidase-labeled streptavidin (SAV-HRP) was added to
incubate for 30 min, followed by washing, and a tetra-
methylbenzidine (TMB) substrate incubation to produce a
colorimetric solution. The intensity of this colored prod-
uct was directly proportional to the concentration of olig-
omeric Aβ in the sample. The standards provided a linear
curve and the best-fit line determined by linear regression
were used to calculate the concentration of Aβ oligomers
in samples.
Assessment of Tau pathology in the brain
Western blot analysis of phosphorylated and total tau
Standard Western blot analysis was first performed on
brain extracts (10% BH) that represents the supernatant
(S1) obtained after centrifuging the brain homogenate at
low speed (20,000 × g for 20 min). Proteins of different
solubility were further extracted from brains in buffers
of increasing stringency. The brain homogenates were
subjected to DEA and FA extraction as described above.
High speed supernatants of DEA extraction were col-
lected and used for Western blot analysis of DEAsoluble fraction. Insoluble proteins were extracted with
FA (FA fraction) [33]. Protein concentration of 10% BH
and both fractions were determined using bicinchoninic
acid assay (BCA; Pierce Biotechnology, Rockford, IL).
Equal amount of protein (20 μg) was loaded and the
samples were electrophoresed on 10% SDS-PAGE gels
and transferred to nitrocellulose membranes. The blots
were blocked in 5% non-fat milk with Tween-20 in TBS,
and incubated with the following mouse monoclonal pri-
mary antibodies overnight at 4°C: PHF1 (Ser396/Ser404,
1:500), CP13 (Ser202, 1:500), TG5 (total human and
mouse tau, 1:1000) and CP27 (total human tau, 1:1000);
provided by P. Davis. Subsequently, the blots were washed
and incubated for 1 hr at RT with peroxidase-conjugated
goat anti-mouse IgG (1:3000; GE Healthcare UK Limited,
Little Chalfont, UK). The bound antibodies were de-
tected by enhanced chemiluminescence (ECL; Pierce
Biotechnology, Rockford, IL). Densitometric analyses of
the immunoreactive bands corresponding to phospho-tau
and/or total tau were performed with NIH Image J software
(version 1.34). The levels of pathological tau were nor-
malized relative to β-actin.
Sandwich ELISA for phospho-tau (pS199) and (pS396)
Quantitative determination of human tau phosphory-
lated at pS396 and pS199 in 10% BH was performed
using an Invitrogen Human tau ELISA kit (Invitrogen
Corporation, Camarillo, CA) as we previously published
[34]. Briefly, a monoclonal antibody specific for all forms
of human tau (phosphorylated and non–phosphorylated)
was pre-coated onto wells of microtiter strips. 10% BH
were centrifuged at 20,000 × g for 20 min at 4°C. Samples
diluted in the provided standard diluent buffer (1:200)
were incubated for 2 hrs at room temperature allowing
antigen to bind the immobilized (capture) antibody,
followed by extensive washing and incubation for 1 hr at
RT with detection antibody [rabbit polyclonal antibody
specific for human tau (pS396 or pS199)] which binds to
the immobilized human tau (pS396 or pS199) captured
during the first incubation. After removal of excess anti-
body, horseradish peroxidase-labeled anti-rabbit IgG anti-
body was incubated for 30 min, followed by washing, and
3,3’,5,5’ -tetramethylbenzidine (TMB) substrate incubation
to produce color. The intensity of this colored product
was directly proportional to the concentration of human
tau pS396 or pS199 present in the sample. The standards
provided a linear curve and the best-fit line determined by
linear regression were used to calculate human tau pS396
or pS199 concentration in our samples.
Immune response analyses
Measurements of cytokine production to evaluate the
Th subset induced and autoantibody responses towards
Aβ42 were evaluated in plasma, utilizing the NYULMC
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immunization and every month thereafter including a
sacrifice bleed. Since a limited amount of blood can be
analyzed, the peripheral cytokine responses were deter-
mined in plasma at selected time points throughout the
treatment period.
Cytokine assays
Cytokine profiles in plasma from CpG ODN-treated
and control animals were analyzed using MILLIPLEX-
MAP mouse cytokine/chemokine magnetic bead panel
(EMD Millipore Corporation, Billerica, MA), after the
i.p. injection of either CpG ODN or saline at 4 hrs
post-injection every month throughout the course of
treatment. T final (at the time of sacrifice) was collected
4 weeks after the last injection (after the completion of
behavioral studies). Separate cytokine analyses were
also performed in plasma samples collected 2 weeks
after selected injections to evaluate the kinetic patterns
of cytokine induction. Additionally, cytokine levels were
assessed in single plasma samples collected from a sep-
arate cohort of 3xTg-AD mice during our short term
study at the time of sacrifice (12 hrs post-injection).
Brain cytokines levels were also screened 12 hrs after
CpG ODN or saline i.p. administration. These assays
allow quantification of an array of cytokines in a single
small volume sample. A custom 10-plex detection kit,
which measured IL1β, IL4, IL6, IL10, MCP1, TNFα,
IFNγ, IL13, IP10 and IL12p70 was used. The manufac-
turer’s instructions were followed. Briefly, plasma sam-
ples (1:3 dilution - serum matrix) or supernatants of
10% (w/v) brain homogenates (centrifuged at 10,000 ×
g for 5 min at 4°C) were incubated with a mixture of
Abs conjugated with fluorescent beads overnight. Fol-
lowing the biotinylated detection Ab and streptavidin-
PE conjugate incubations, levels of each cytokine were
measured using the Luminex 200™ analyzer (Immune
Monitoring Core). Median Fluorescent Intensity (MFI)
data were analyzed with ExPONENT software using a
5-parameter logistic curve-fitting method for calculat-
ing cytokine/chemokines concentrations in samples.
Concentrations were calculated from standard curves
and are expressed in pg/ml.
Aβ autoantibody response
The autoantibody levels were determined at 1:200 dilutions
of plasma using ELISA as described previously in which
50 μg per plate of the Aβ42 peptide was coated onto mi-
crotiter wells (Immulon 2HB; Thermo, Waltham, MA) [9].
The antibodies in plasma were detected by a goat anti-
mouse IgG linked to a horseradish peroxidase conjugate
(Sigma; A8786) at 1:3000 dilution. Tetramethylbenzidine
(TMB; Bio-Rad Laboratories Inc., Hercules, CA) was the
development substrate.Statistical analysis
Data from the radial arm maze were analyzed by two-way
repeated measures ANOVA followed by a Bonferroni’s
post hoc test. Data from the accelerating rotarod and loco-
motor test were analyzed by one-way ANOVA. Differ-
ences between groups in total amyloid burden, fibrillar
amyloid burden, tau burden, levels of extracted Aβ, levels
of Aβ oligomers, phospho-tau/total tau levels in brain
homogenates, Iba1, CD45, CD11b, CD206 activated
microglia, GFAP astrogliosis, brain microhemorrhages,
and cytokine levels were analyzed using a Student’s un-
paired two-tailed t test or one-tailed t test. All statis-




After treatment, at the age of 18 or 20 months, mice
were subjected to behavioral testing. Behavioral analysis
consisted of both a cognitive assessment and measure-
ment of sensorimotor abilities. The latter tests were in-
cluded to verify that performance on cognitive testing
was not influenced by sensorimotor abnormalities. The
transgenic (Tg) mice were less active than their wild-
type (Wt) littermates, but significant differences were
not observed between the treated and control Tg mice
in any of the locomotor parameters measured (velocity,
distance traveled, resting time) (Figure 1A-H). Group
differences were observed in distance traveled (ANOVA,
7–20 months, p < 0.0001; 11–18 months, p = 0.03), aver-
age speed (ANOVA, 7–20 months, p = 0.001; 11–18
months, p = 0.009), resting time (ANOVA, 7–20 months,
p < 0.0001; 11–18 months, p = 0.008) and maximum
speed (ANOVA, 7–20 months, p = 0.0013; 11–18 months,
p = 0.053).
Post hoc analysis revealed that the Wt mice traveled
more distance, moved at a faster speed, and rested less
than CpG ODN-treated Tg mice or Tg controls in the
7–20 month study group (maximum speed: Tg-CpG vs
Tg-VEH, p = 0.19; Tg-CpG vs Wt, **p = 0.0068; Tg-VEH
vs Wt, **p = 0.0026, Figure 1A; average speed: Tg-CpG
vs Tg-VEH, p = 0.82; Tg-CpG vs Wt, **p < 0.002; Tg-VEH
vs Wt, ***p = 0.0005, Figure 1B; distance traveled: Tg-
CpG vs Tg-VEH, p = 0.86; Tg-CpG vs Wt, ***p < 0.0001;
Tg-VEH vs Wt, ***p = 0.0008, Figure 1C; resting time:
Tg-CpG vs Tg-VEH, p = 0.64; Tg-CpG vs Wt, ***p <
0.0001; Tg-VEH vs Wt, ***p = 0.0009, Figure 1D).
CpG ODN Tg mice and Tg controls in the 11–18
month study group performed in a similar matter in all
of the measured locomotor parameters; however, there
were significant differences between Wt and control Tg
mice in three of the parameters (distance, resting time,
average speed). The differences between Wt and CpG
ODN Tg mice did not reach significance (maximum
Figure 1 Sensorimotor tests. Locomotor activity test. (A-D) Treatment from 7–20 months. Both Tg groups were less active than their Wt
age-matched littermates, but the CpG ODN-treated and control Tg mice did not differ significantly in any of 4 locomotor parameters measured [max
speed (A), average speed (B), distance traveled (C), resting time (D)]. (E-H) Treatment from 11–18 months. Tg mice were less active than Wt animals,
but the maximum speed did not differ between the groups. (E) Our treated and control Tg groups did not differ in any of the locomotor parameters
measured [max speed (E), average speed (F), distance traveled (G), resting time (H)]. In addition, no significant differences were detected between
CpG ODN Tg group and Wt mice. See Results section for p values. Rotarod. (I-J) No group differences were observed on the rotarod in both study
groups. The error bars show SEM. This applies to all subsequent figures.
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p = 0.69; Tg-VEH vs Wt, p = 0.26, Figure 1E; average
speed: Tg-CpG vs Tg-VEH, p = 0.24; Tg-CpG vs Wt,
p = 0.157; Tg-VEH vs Wt, **p = 0.003, Figure 1F; dis-
tance traveled: Tg-CpG vs Tg-VEH, p = 0.32; Tg-CpG
vs Wt, p = 0.17; Tg-VEH vs Wt, **p = 0.003, Figure 1G;
resting time: Tg-CpG vs Tg-VEH, p = 0.21; Tg-CpG vs
Wt, p = 0.086; Tg-VEH vs Wt, ***p = 0.0003,
Figure 1H). Maximum speed did not differ between the
groups in the 11–18 month study group. No statistical dif-
ferences were observed between the groups in their per-
formance on the rotarod (Figure 1I-J). In addition to
sensorimotor evaluation, the mice underwent a cognitive
assessment. Working memory was evaluated using an
eight-arm radial maze. As shown in Figures 2A and B, the
overall performance (number of errors) of the micediffered significantly between Tg groups. CpG ODN-
treated Tg groups navigated the radial arm maze with
fewer errors than the vehicle-treated Tg groups, and their
performance was similar to that of their age-matched Wt lit-
termates. VehicleTgmicemade significantlymore errors than
Wt animals [7 to 20 months: Two-way repeated-measures
ANOVA, group (treatment) effect, p < 0.0001; days effect, p <
0.0001; interaction (group vs days), p= 0.968. Bonferroni’s
post hoc test showed Tg-CpG vsTg-VEH, p < 0.0001; Tg-CpG
vsWt, p = 0.16; Tg-VEH vsWt, p < 0.0001; 11 to 18 months:
Two-way repeated-measures ANOVA, group (treatment) ef-
fect, p < 0.0001; days effect, p < 0.0001; interaction (group vs
days), p= 0.795. Bonferroni’s -post hoc test showed Tg-CpG
vs Tg-VEH, p < 0.001; Tg-CpG vs Wt, p= 0.2; Tg-VEH vs
Wt, p < 0.001]. The groups did not differ significantly in the
time taken to run the maze (data not shown).




































Figure 2 Radial arm maze (working memory assessment). TLR9 stimulation was effective at improving working memory in 3xTg-AD mice in
both study groups. The CpG ODN-treated groups were better at navigating the maze than the vehicle-treated Tg mice. Significant differences
were observed with CpG ODN-treated Tg mice performing comparably to their Wt littermates. (A) 7–20 months: Two-way repeated-measures
ANOVA, group (treatment) effect, p < 0.0001; days effect, p < 0.0001; interaction (group vs days), p = 0.968. Bonferroni’s post hoc test revealed
Tg-CpG vs Tg-VEH, p < 0.0001; Tg-CpG vs Wt, p = 0.16; Tg-VEH vs Wt, p < 0.0001. (B) 11–18 months: Two-way repeated-measures ANOVA, group
(treatment) effect, p < 0.0001; days effect, p < 0.0001; interaction (group vs days), p = 0.795. Bonferroni’s post hoc test revealed Tg-CpG vs Tg-VEH,
p < 0.001; Tg-CpG vs Wt, p = 0.2; Tg-VEH vs Wt, p < 0.001.
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Quantification of amyloid burden
We next assessed the effects of CpG ODN in 3xTg-AD
mice on Aβ pathology. The mice were sacrificed at 19 and
21 months of age after behavioral testing and the brains
were processed for histology. Quantitative analysis was de-
termined by stereological techniques, using an unbiased
random sampling scheme and a semi-automated image
analysis system as described previously [9].
Histological observation in 3xTg-AD mice indicated
that CpG ODN-treated mice have fewer plaques com-
pared to vehicle Tg mice as visualized by immunostain-
ing (using anti-Aβ 6E10/4G8) in both study groups
(Figure 3A-H). In the 7–20 month study group, periph-
eral administration of TLR9 agonist CpG ODN led to a
67% reduction (two-tailed t test, **p = 0.018) in total cor-
tical amyloid burden and a 47% reduction (*p = 0.0032)
in total hippocampal amyloid burden compared to age-
matched vehicle Tg animals (Figure 3I-J). In the 11–18
month study group, there was a 64% reduction (*p =
0.047) in total cortical amyloid burden and a 60% reduc-
tion (**p = 0.0013) in total hippocampal amyloid burden
in 3xTg-AD mice treated with CpG ODN compared to
control Tg mice treated with vehicle (Figure 3K-L).
Thioflavine-S staining was used to demonstrate fibrillar
amyloid plaque accumulation and CAA load (Figure 4A-D).
Quantitative assessment of hippocampal fibrillar amyloid
burden revealed a significant 58% reduction (two-tailed
t test, ***p = 0.0004) in CpG ODN-treated animals
compared to controls in the 7–20 month study group
(Figure 4E). A 57% reduction (***p = 0.0004) of the fi-
brillar amyloid burden was observed in the 11–18
month study group (Figure 4F). Thioflavine-S stainingof amyloid depositions was observed mainly in the
hippocampus. Moreover, visible reductions were revealed
in the CAA burden of the penetrating cortical and hippo-
campal vessels in the CpG ODN-treated animals com-
pared to controls in both age groups (Figure 5A-B). CpG
ODN treatment led to a 74% reduction (two-tailed t test,
*p = 0.03) in the vascular amyloid burden in the 7–20
study group (Figure 5C). Similar effects were seen in the
11–18 month study group. An 80% reduction (*p = 0.036)
in the vascular amyloid was noted in the CpG ODN-
treated animals (Figure 5D). Brain microhemorrhages
were detected in 3xTg mouse brain sections stained
with Perl’s stain. Following treatment with CpG ODN
we observed a significant decrease in the extent of cere-
bral microhemmorhages (7–20 study group, one-tailed
t test, *p = 0.034; 11–18 study group, one-tailed t test,
*p = 0.043) (Figure 5E-H).
Assessment of Aβ levels, Aβ oligomers in the brain
Stimulation of TLR9 signaling significantly decreased
total (FA extract) and soluble (DEA extract) brain Aβ
levels in 3xTg-AD mice, in both study groups. ELISA
measurements revealed a statistically significant decrease
in the levels of total (FA extracted) Aβ40 and Aβ42 by
54% (two tailed t test, *p = 0.04) and 61% (*p = 0.04), re-
spectively, after the CpG ODN treatment in the 7–20
month study group (Figure 6A). The levels of soluble
(DEA extracted) Aβ40 and Aβ42 fractions were signifi-
cantly reduced by 50% (two-tailed t test, ***p = 0.0009)
and 70% (*p = 0.019), respectively, in CpG ODN-treated
mice in the 7–20 month study group (Figure 6B). Treat-
ment from 11 to 18 months significantly lowered total









Figure 3 Total amyloid burden. Immunohistochemistry (6E10/4G8) showed a notable reduction in total amyloid burden in cortical and
hippocampal sections of CpG ODN-treated mice compared with sections of vehicle-treated mice in both study groups (A-H). Quantitative stereological
analysis of total amyloid burden revealed a significant reduction in 3xTg-AD mice treated with CpG ODN compared with control Tg mice. There was a
67% reduction (**p = 0.018) in total cortical amyloid burden (I) and 47% reduction (*p = 0.0032) in total hippocampal amyloid burden (J) in the 7–20
month study group. Similarly, there was a 64% reduction (*p = 0.047) in total cortical amyloid burden (K) and 60% reduction (**p = 0.0013) in total
hippocampal amyloid burden (L) in the 11–18 month study group. Scale bars (100 μm) in B and F correspond to cortical images A, B, E, F. Scale bars
in D and H correspond to hippocampal images C, D, G, H.
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uble Aβ40 and Aβ42 brain levels by 44% (two-tailed t
test, *p = 0.047 and 53% *p = 0.019) (Figure 6C-D).
Soluble Aβ oligomers (also known as ADDLs) may
account for synaptotoxicity and cognitive impairment,
thus presenting a significant therapeutic target. Patho-
genic Aβ oligomers in the brain homogenates were
assessed by Western blot using the A11 oligomer-specific
antibody (Figure 7A-B). CpG ODN treatment led to asignificant decrease in the level of A11 immunoreactive
(approximately 32 kDA and 28 kDa) oligomers in the
11–18 month study group (32 kDA, two-tailed t test,
*p = 0.015; 28 kDa, two-tailed t test, *p = 0.023). No dif-
ference was found in the 7–20 month study group (data
not shown). We focused on oligomers in the range of
~32 kDa similar to our prior published work and that
of others [30,35,36]. Different groups have focused on





Figure 4 Fibrillar amyloid burden. Thioflavine-S staining revealed significant differences in hippocampal fibrillar amyloid burden between CpG
ODN-treated and vehicle-treated 3xTg-AD mice (A-D). Thioflavine-S staining of amyloid depositions was minimal in the cortex. There was a 58%
reduction (***p = 0.0004) in hippocampal fibrillar amyloid burden in the 7–20 month study group (E) and a 57% reduction (***p = 0.0004) in
hippocampal fibrillar amyloid burden in the 11–18 month study group (F) as quantified using an unbiased random sampling scheme and





Figure 5 Vascular amyloid (CAA burden) and brain microhemorrhages. Representative images of a visible reduction in the CAA burden of
the cortical vessels in mice treated from 7–20 months are shown in A and B. Significantly, CpG ODN treatment led to a 74% (*p = 0.03) reduction
in the vascular amyloid burden in the 7–20 month study group (C) and an 80% reduction (*p = 0.036) was noted in CpG ODN-treated animals in
the 11–18 month study group (D) measured by unbiased stereology. E and F show representative 3xTg-AD mice brain sections stained with Perl’s
stain for ferric iron in haemosiderin. Quantification of CAA-associated microhemorrhages revealed a significant reduction of iron positive profiles
per brain section in CpG ODN-treated animals in both study groups (7–20 study group, *p = 0.034; 11–18 study group, *p = 0.043) (G,H). Scale
bar, 100 μm.




Figure 6 Brain Aβ levels. Treatment from 7–20 months significantly lowered total (FA extracted) Aβ40 and Aβ42 levels by 54% (*p = 0.04) and
61% (*p = 0.04), respectively (A). Soluble (DEA extracted) Aβ40 and Aβ42 fractions were also significantly reduced by 50% (***p = 0.0009) and 70%
(*p = 0.019), respectively (B). Treatment in the 11–18 month study group significantly decreased total Aβ40 and Aβ42 brain levels by 69% (*p = 0.03)
and 64% (*p = 0.026), respectively (C) and soluble Aβ40 and Aβ42 by 44% (*p = 0.047) and 53% (*p = 0.019) (D), as assessed by sandwich ELISA.
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come dissociated during processing and when run on
SDS-polyacrylamide gel electrophoresis [38], leading to
variation in their molecular weight.
Due in part to this variability, we further evaluated
CpG ODN treatment effect by an ELISA specific to olig-
omeric Aβ as previously published [18,19]. Stimulation
of TLR9 signaling significantly decreased Aβ aggregates/
oligomers in 3xTg-AD mice, in both study groups (7–20
month study group: one-tailed t test, *p= 0.03; 11–18 month
study group: two-tailed t test, *p= 0.04, Figure 7C-D).
Tau pathology
Quantification of Tau burden
To determine the efficacy of CpG ODN on the tau path-
ology we immunohistochemically evaluated sections from
CpG ODN- and vehicle-treated 3xTg-AD mice with differ-
ent anti-tau antibodies. The early conformation specific
antibody MC1, and antibodies recognizing phospho-tau
epitopes Ser202/Thr205 (AT8) and Ser396/Ser404 (PHF1)
are among the most characterized identifiers of neuro-
fibrillary pathology. The effects were mainly limited to
the hippocampus since cortical MC1, AT8 and PHF1immunoreactivity was minimal. Significant reductions
of phospho-tau were noted in CpG ODN-treated ani-
mals in both study groups. Semiquantitative analysis of
neuronal immunoreactivity in the hippocampus revealed
significant reductions in AT8 (two-tailed t test, **p =
0.028) PHF1 (one-tailed t test, *p = 0.049) and MC1
(one-tailed t test, *p = 0.036) tau markers in CpG
ODN-treated 3xTg-AD mice compared with control
mice that received vehicle only in the 7–20 month
study group (Figure 8E-G).
AT8 and PHF1 immunostained coronal sections of
mice treated from 11 to 18 months indicated visible dif-
ferences between the groups (Figure 8H-K). There were
significant reductions in AT8 (two-tailed t test, **p =
0.0075) and PHF1 (one-tailed, *p = 0.03) immunoreactiv-
ity in CpG ODN-treated 3xTg-AD mice compared with
vehicle-treated Tg controls. Strong trend for a dimin-
ished MC1 (one-tailed t test, p = 0.06) immunoreactivity
was observed in treated animals compared with controls
in the 11–18 month study group (Figure 8L-N). In
addition, the level of total tau (HT7 immunoreactivity)




Figure 7 Assessment of Aβ oligomers. Western blot of brain homogenates labeled with A11 oligomer-specific antibody (A) and densitometric
analysis of A11 immunoreactive oligomer specific bands (approximately 32 kDA and 28 kDa, in arbitrary O.D. units) showed a significant reduction
in CpG ODN-treated Tg mice compared with control Tg mice in the 11–18 month study group (32 kDA, *p = 0.015; 28 kDa, *p = 0.023) (B). As
further assessed by an ELISA specific to oligomeric Aβ, CpG ODN treatment led to a significant decrease in Aβ oligomers in both study groups
(7–20 month study group, *p = 0.03; 11–18 study group, *p = 0.04) (C, D).
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To further determine the extent of tau pathology in 3xTg-
AD mice after CpG ODN administration, we carried out
multiple biochemical analyses. Standard Western blot
analysis was first performed on soluble brain extracts that
represents the supernatant obtained after centrifuging the
brain homogenate at low speed (S1). Total tau was mea-
sured with TG5 (total human and mouse tau) and CP27
(total human tau) antibody whereas pathological tau was
detected with phosphorylation site-specific monoclonal
antibodies PHF1 (Ser396/Ser404) and CP13 (Ser202).
Densitometric analysis revealed significant reduction in
soluble CP13 tau levels (two tailed t test, *p = 0.035), when
normalized to actin, after CpG ODN treatment in the 11–
18 month study group (Figure 10A-B). A strong trend was
observed for a decrease in PHF1 reactive tau (one tailed t
test, p = 0.07, data not shown). No differences were found
on PHF1 or CP13 tau blots in the 7–20 month study
group (data not shown). To further determine the levelsof soluble and insoluble tau we performed sequential bio-
chemical extractions. Measurements of soluble tau in
DEA brain fraction did not reveal a reduction between the
groups in the 7–20 month study group. However, there
was a strong trend toward reduced PHF1 (one tailed t test,
p = 0.086, Figure 10C-D) and CP13 tau levels (data not
shown) in the DEA soluble fraction for CpG ODN-treated
animals in the 11–18 month study group. Insoluble tau
protein was extracted with FA. Our further analysis in FA
brain fraction indicated a trend for reduced insoluble
PHF1 tau levels in the CpG ODN-treated animals
compared to controls in the 7–20 month study group
(one tailed t test, p = 0.08, Figure 10E-F). No statistical
differences in the levels of PHF1 or CP13 immunoreactivity
were detected between CpG ODN-treated mice and
control animals in the 11–18 month study group
(data not shown). Furthermore, total tau levels (CP27)
(Figure 10G-H) and TG5 (data not shown) remained un-
changed in all treatment groups.
A B C D
H I J K
L M N
E F G
Figure 8 Histological evaluation of pathological tau. Representative images of AT8 and PHF1 immunostaining within the hippocampus
depicted differences between CpG ODN-treated and vehicle-treated 3xTg-AD mice in both study groups (A-D), (H-K). Semiquantitative analysis of
hippocampal neurons revealed reductions in AT8 (**p = 0.028) (E), PHF1 (*p = 0.049) (F) and MCI (*p = 0.036) (G) immunoreactivity in treated mice
compared with control mice in the 7–20 month study group. Likewise, significant reductions were observed in AT8 (**p = 0.0075) (L) and PHF1
(*p = 0.03) (M) immunoreactive tau in CpG ODN-treated animals in the 11–18 month study group. There was a trend for reduced MCI
immunoreactivity in treated animals from 11 to 18 months (p = 0.06) (N). Scale bars, 100 μm.
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flammation in the brain can influence subsequent devel-
opment of tau pathology [11-16]. To confirm that
stimulation of innate immunity with TLR9 agonist, CpG
ODN, does not accelerate formation of tau depositions
as previously demonstrated in a number of studies using
TLR4 agonists (LPS) [16,39,40], we performed additional
analyses of tau pathology. Quantitative determination of
tau phosphorylated at (pS396) and (pS199) in 10% BH
was performed by ELISA using a Human Tau ELISA
kit, and showed no differences between the groups
(Figure 11A-D). Overall, our thorough biochemical
analyses did not show as robust treatment effect asobserved with immunohistochemistry. This may be re-
lated to the fact that all biochemical analyses were per-
formed in brain fractions of the whole hemisphere and
not from fractions of micro-dissected specific brain
regions.
Associated histopathology
Assessment of microgliosis and astrogliosis
Subsequent evaluation of CpG ODN treatment effect on
microglial activation was performed. Analysis of com-
monly used microglial and macrophage marker CD45,
which is typically expressed in association with more









Figure 9 Histological evaluation of total tau. Representative images of HT7 immunostained cortical and hippocampal brain sections from
control and treated mice (A-H), and subsequent semiquantitative analysis (I-L) did not reveal any significant differences in total tau levels between
CpG ODN-treated and vehicle-treated Tg animals in both study groups. Scale bars (100 μm) in B and F correspond to cortical images A, B, E, F. Scale
bars in D and H correspond to hippocampal images C, D, G, H.
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CD45 microglial activity in CpG ODN- treated mice was
observed at the end of the study in both age groups
(Figure 12A-D). Quantitative stereological analysis dem-
onstrated 44% reduction (two-tailed t test, **p = 0.008) in
CD45 reactive microglia burden in the 7–20 month
study group and 52% reduction (**p = 0.0065) in the
11–18 month study group (Figure 12E-F). The staining
intensity of CD45 marker was very low in the cortex
(data not shown). Similarly, 3xTg-AD mice treated withCpG ODN exhibited an overall decrease in hippocampal
CD206 (marker of M2 state of alternative activation)
immunoreactivity at the end of the treatment (two-
tailed t test, 7–20 months, *p = 0.04; 11–18 months,
*p = 0.013, Figure 12G-L). Cortical CD206 immunoreactiv-
ity was minimal and was not quantitated (data not shown).
The assessment of another well-established microglial/
mononuclear phagocyte marker CD11b was based on
semiquantitative analysis of the extent of microgliosis.
CpG ODN reduced overall cortical (two-tailed t test,
Figure 10 (See legend on next page.)
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Figure 10 Western blot analysis of phosphorylated and total tau. Densitometric analysis showed a significant reduction in soluble (S1
fraction) CP13 phospho-tau levels (*p = 0.035) when normalized to actin, in the 11–18 month study group (A, B). Additional analysis indicated a
trend for a decrease in PHF1 reactive tau in the same treatment group (p = 0.07) (data not shown). No statistically significant changes were
observed in Western blot analysis of DEA soluble brain fraction, but there was a notable trend in reduction of PHF1 (p = 0.086) (C, D) and CP13
DEA soluble tau levels (data not shown) in CpG ODN-treated mice in the 11–18 month study group. The groups did not differ significantly in their
levels of insoluble (FA brain fraction) CP13 or PHF1 tau; however, there was a trend for reduced insoluble PHF1 tau levels in the CpG ODN-treated
animals compared to controls in the 7–20 month study group (p = 0.08) (E, F). Furthermore, no differences in total tau assessed by CP27 were detected
between our treated and control 3xTg-AD animals. Total tau levels were not affected by CpG ODN treatment in both study groups (G, H). G shows
representative western blot from control and CpG ODN mice treated from 7 to 20 months. The same amount of protein was loaded in each lane of
the Western blots.
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reactivity in the 11–18 month study group (Figure 12M-R).
No difference in CD11b reactive microglia was found in
the 7–20 month study group (data not shown). The
Iba1 microglial marker labels both resting and activated
microglia populations [28,29]. In contrast, no differ-
ences in cortical and hippocampal Iba1 immunoreactivity
were found comparing CpG ODN-treated and vehicle-A
C
Figure 11 Assessment of phosphorylated and total tau by ELISA. Furt
performed in brain homogenate fractions of the whole hemisphere by usin
animals in both study groups (A-D).treated animals in both study groups (Figure 13). As
assessed by GFAP immunoreactivity, followed by semi-
quantitative analysis, no significant differences were
observed between the groups in the degree of astro-
gliosis (data not shown). To further determine if any
neuroinflammation was induced, the brains were ex-
amined for the presence of lymphocytic infiltration.
No T cells (CD3) were detected in any region of theB
D
her quantitative analysis of phospho-tau (pS396) and (pS199) was
g ELISA and showed no differences between our treated and control
Figure 12 (See legend on next page.)
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Figure 12 Assessment of CD45, CD206 and CD11b microgliosis. CpG ODN reduced overall hippocampal CD45 immunoreactivity in both
treatment groups (A-D). Quantitative stereological analysis revealed 44% reduction (**p = 0.008) in CD45 reactive microglia burden in the 7–20
month study group and 52% reduction (**p = 0.0065) in the 11–18 month study group (E, F). Cortical CD45 immunoreactivity was minimal. Scale
bar, 100 μm. Immunostaining with CD206 (G-J) followed by semiquantitative analysis demonstrated significant reduction in hippocampal CD206
positive cells in both age groups (7–20 months, *p = 0.04; 11–18 months, *p = 0.013) (K, L). Cortical CD206 was minimal. The degree of CD206
microgliosis was graded on a scale of 0–4. Scale bar, 100 μm. Representative immunostained images with CD11b microglia marker (M-P) and
subsequent semiquantitative analysis of CD11b immunoreactivity revealed marked cortical (*p = 0.037) and hippocampal (*p = 0.015) reductions in
CpG ODN-treated mice in the 11–18 month study group (Q, R). The degree of CD11b microgliosis was analyzed on a scale of 0–4. Scale bar





Figure 13 Assessment of Iba1 microgliosis. Histological observations (A-H) and semiquantitative rating of Iba1 microglial staining did not
reveal group differences in the degree of cortical and hippocampal Iba1 immunoreactivity (I-L). Iba1 microgliosis was rated on a scale of 0–4.
Scale bars (100 μm) in B and F correspond to cortical images A, B, E, F. Scale bars in D and H correspond to hippocampal images C, D, G ,H.
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Hence, there was no evidence of cerebral inflammatory
toxicity in the brains of CpG ODN- treated mice.
An acute administration of CpG ODN in a separate co-
hort of 3xTg-AD mice was performed to further evaluate
the effects of TLR9 signaling on the macrophage/microglia
activation state and ability to promote phagocytosis. Func-





Figure 14 Assessment of CD45, CD11b and CD206 microglial activatio
ODN led to an induction of favorable microglia/macrophage activation in 3
in CD45 (young, **p = 0.001; aged, *p= 0.01) (A, B), CD11b (young, **p= 0.001
(G, H) macrophage/microglia markers 12 hrs after CpG ODN administratio
cell activation after a single i.p. injection of either CpG ODN or saline was
the hippocampus (C, F, I). Scale bars, 100 μm. CD45 and CD206 positive
restricted to AD pathology. Co-staining of microglial markers (CD45 or CD
CD45 and CD206 immunoreactive microglia around the plaques in mice
microscopy confirmed partial co-localization of CD45 and CD206 positive
co-localization. In addition, double immunofluorescence for microglial ma
indicated an increase in CD45 and CD206 microglial activation in associat
perikarya and neuronal processes, as well as dystrophic neurites (L, M). J
Tg-control and Tg-CpG ODN mice. Similar increase in activation of CD45
observed in 12 month old CpG ODN-injected animals (data not shown). Simmunosenescence in old animals; hence our short term
experiment was performed in young (12 months old) and
aged (20 months old) animals. Semiquantitative analysis
showed a significant increase in hippocampal CD45 (two-
tailed t test, young, **p = 0.001; aged, *p = 0.01,
Figure 14A-C) and CD11b (two-tailed t test, young, **p =
0.0013; aged, *p = 0.02, Figure 14D-F) microglial markers




n states 12 hrs post CpG ODN injection. An acute injection of CpG
xTg-AD mice. Immunohistochemistry indicated a significant increase
3; aged, *p= 0.02) (D, E) and CD206 (young, *p= 0.017; aged, **p= 0.006)
n in both age cohorts of 3xTg-AD mice. The assessment of microglial
based on semiquantitative analysis of the extent of microgliosis in
cells, likely to be infiltrating peripheral macrophages, were clearly
206, green) and Aβ deposits (6E10/4G8, red) revealed an increase in
injected with CpG ODN, 12 hrs post CpG ODN injection. Confocal
microglia with 6E10/4G8 positive Aβ deposits (J, K). Arrows indicate
rkers (CD45 or CD206, green) and pathological tau (MC1, red)
ion with MC1 reactive pathological tau within hippocampal neuronal
- M show representative hippocampal images from 20 month old
and CD206 microglial cells in the vicinity of AD pathology was
cale bars, 50 μm.
Scholtzova et al. Acta Neuropathologica Communications 2014, 2:101 Page 20 of 28
http://www.actaneurocomms.org/content/2/1/101i.p. administration in both age groups. No significant dif-
ferences were noted in microglial density in the cortex
(data not shown). Additional staining was conducted to
further analyze the microglial phenotype using CD206, an
alternative M2 macrophage activation marker [24,26,27].
When examining the stained sections, we noted an in-
creased CD206 hippocampal microglial activation in the
CpG ODN injected animals (two-tailed t test, young,
*p = 0.017; aged, **p = 0.006, Figure 14G-I). The cor-
tical staining intensity of CD206 was minimal (data
not shown). Moreover, CD45 and CD206 immuno-
staining counterstained with anti-Aβ 6E10/4G8 further
confirmed the acute activation state of microglia in
close proximity to Aβ deposits, by revealing an increase
in activated microglia around the plaques in mice injected
with CpG ODN compared to controls (saline injection) in
both age groups (Figure 14J-K). Partial co-localization of
CD45 or CD206 positive microglia with 6E10/4G8 positive
Aβ deposits was often observed in the CpG ODN groups
(Figure 14J-K). Subsequently, we co-stained the brain sec-
tions with pathological tau marker (MC1). Double im-
munofluorescence for MC1 reactive pathological tau
and both microglial markers (CD45 and CD206) dem-
onstrated dense gathering of activated microglia around
pathological tau within hippocampal neuronal perikarya
and processes, as well as dystrophic neurites in CpG
ODN-treated mice in both age cohorts (Figure 14L-M).A
C
Figure 15 Assessment of Iba1 microglial activation 12 hrs post CpG O
affected by acute injection of CpG ODN. Representative hippocampal imag
reactive microglia showed no group differences in both age cohorts (C). Sc
CD45 (green) and Iba1 (red) did not reveal co-localization (D). Scale bar, 50No co-localization was noted between microglial markers
and MC1 immunoreactivity. The microglia/macrophage
activation was increased in the subiculum and CA1 re-
gions of 3xTg-AD mice, which corresponded to the re-
gions of the most intense amyloid and tau depositions. On
the other hand, we found that administration of CpG
ODN did not alter Iba1 immunoreactivity. No differences
were detected in the number of Iba1 positive cells between
groups (Figure 15A-C). Furthermore, co-staining for Iba1
and CD45 microglia did not reveal co-localization
(Figure 15D). These observations highlight the importance
of assessing the activation states of microglia that may
have contributed to CpG ODN therapeutic outcomes.
Characterization of immune responses
Aβ autoantibody levels
We next set out to test whether the CpG ODN thera-
peutic effect had any relationship with the production of
anti-Aβ antibodies. The autoantibody response towards
Aβ42 was assessed periodically. Stimulation of TLR9 sig-
naling did not lead to generations of anti-Aβ42 antibody
in CpG ODN-treated Tg mice when compared with
vehicle-treated Tg mice. No differences were observed in
the levels of autoantibodies in plasma obtained at the end
of the study in both age groups (Figure 16). Hence, stimu-
lation of innate immunity with CpG ODN did not lead to
secondary activation of adaptive immunity against Aβ.B
D
DN injection. Accumulation of Iba1 immunoreactive cells was not
es (A, B) and subsequent semiquantitative comparisons of Iba1
ale bar, 100 μm. Note that double immunofluorescence labeling with
μm.
Figure 16 Levels of autoantibodies. No apparent differences were
observed in the autoantibody response towards Aβ42 in plasma
collected at the end of the study among CpG ODN-treated and
vehicle-treated Tg mice in both study groups, as assessed by ELISA.
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Analysis was performed to assess whether administration
of CpG ODN in 3xTg-AD mice was effective in inducing
immunostimulatory response in the absence of any tox-
icity. Cytokine profiles in plasma collected 4 hrs after an
i.p. injection of CpG ODN or saline were measured at
monthly intervals, using the Th1/Th2 Luminex mouse
cytokine/chemokine kit. Statistical analyses of cytokine
profiles in plasma collected pre and post 1st CpG ODN
administration revealed significant differences as shown
in Figure 17A-R. There was a noticeable increase in
TNFα [7–20 months, two-tailed t-test (applies to all sub-
sequent t-tests for cytokine responses), ***p = 0.0001,
Figure 17A; 11–18 months, ***p = 0.0002, Figure 17J]
and IFNγ plasma levels 4 hrs post CpG ODN adminis-
tration compared to saline animals (7–20 months, *p =
0.017, Figure 17B; 11–18 months, *p = 0.01, Figure 17K).
An evident increase in IL12p70 was observed in the 7–
20 month study group (*p = 0.002, Figure 17C). IL12p70
cytokine was detected in low levels and no significant
differences were observed between the treatment groups
at various time points in the 11–18 months age group.
Our subjects showed a strong induction of IL6 plasma
levels (7–20 months, **p = 0.007, Figure 17D; 11–18
months, **p = 0.004, Figure 17M). In addition, higher peak
plasma levels of IP10 (Interferon gamma-induced protein
1 also known as CXCL10), and MCP1 (monocyte chemo-
tactic protein-1 also known as CCL2) chemokines were
observed after CpG ODN injection in the 7–20 month
study group (IP10, ***p < 0.0001, Figure 17E; MCP1, **p =
0.002, Figure 17F). Similar effects were seen in the 11–18
month study group (IP10, **p < 0.008, Figure 17N; MCP1,
*p = 0.04, Figure 17O). IL1β elevation has been linked to
induction of tau related pathology [41]. Of interest to us,
IL1β, a potent inflammatory cytokine, was detectable at
very low levels, and exhibited no significant changes over
time between the groups (Figure 17G, P). Furthermore,
IL10, a potent anti-inflammatory cytokine, was alsosignificantly induced in response to stimulation with
CpG ODN in both aged groups (7–20 months,
**p = 0.002, Figure 17H; 11–18 months, *p = 0.01,
Figure 17Q). Results for IL4 showed most measure-
ments to be near the detection limit and no differences
were observed between the groups (data not shown).
There was a strong trend toward increase in IL13
plasma levels in our treated groups (7–20 months,
p = 0.09, Figure 17I; 11–18 months, p = 0.1 Figure 17R).
Separate plasma cytokines analysis were also performed in
plasma samples collected 2 weeks after selected injections
to evaluate the kinetic pattern of cytokine induction
(Figure 17A-R). As expected, 2 weeks after the first injec-
tion, the levels of TNFα (7–20 months, ***p < 0.0001,
Figure 17A; 11–18 months, ***p < 0.0001, Figure 17J),
IFNγ (7–20 months, *p = 0.028, Figure 17B; 11–18
months, **p = 0.026, Figure 17K), IL12p70 (7–20 months,
*p = 0.049, Figure 17C), IL6 (7–20 months, *p = 0.018,
Figure 17D; 11–18 months, ***p < 0.0001, Figure 17M),
IP10 (7–20 months, ***p < 0.0001, Figure 17E; 11–18
months, ***p < 0.0001, Figure 17N), MCP1 (7–20 months,
**p = 0.026, Figure 17F; 11–18 months, **p = 0.008,
Figure 17O), IL10 (7–20 months, **p = 0.006, Figure 17H;
11–18 months, ***p < 0.0001, Figure 17Q), IL13 (7–20
months, *p = 0.03, Figure 17I) were significantly lower
than what was observed in plasma collected 4 hrs post 1st
CpG ODN administration. Since the levels of IL12p70
were limited and only slightly enhanced compared to sa-
line treated animals in the 11–18 month study group, no
difference was observed at the two week time point
(Figure 17L). IL13 decreased 2 weeks later but did not
reach statistical significance (11–18 month study group,
Figure 17R). Similar cytokine responses were detected in
plasma samples collected 4 hrs or 2 weeks after subse-
quent monthly injections.
Furthermore, no significant differences in cytokine
levels were found between the groups at the time of sac-
rifice, 4 weeks after the last CpG ODN injection. The
cytokine levels subsided over time (data not shown).
Overall, TLR9 agonist CpG ODN elevated the levels of
various Th1/Th2 cytokines-chemokines, but the levels
were considerably lower than what was observed in pre-
vious reports with TLR4 agonist LPS [42,43]. Our find-
ings demonstrate that stimulation of TLR9 signaling
with CpG ODN seems to induce a suitable degree of in-
nate immune stimulation that reduces the accumulation
of AD related pathology, without producing excessive
and sustained inflammation.
We next examined the plasma and brain cytokine re-
sponses to acute TLR9 signaling stimulation. Plasma
cytokine profiles assessed at the time of sacrifice,
12 hrs after CpG ODN or saline i.p. administration,
were comparable to the induction of plasma cytokines
observed in our original long term study (data not
Figure 17 (See legend on next page.)
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Figure 17 Plasma cytokine/chemokine analysis (long term study). Luminex analysis (Th1/Th2 mouse cytokine/chemokine detection kit) was
used to determine immunostimulatory responses induced by CpG ODN in the plasma of 3xTg-AD mice. Results are expressed as pg/ml of TNFα,
IFNγ, IL12p70, IL6, IP10, MCP1, IL1β, IL10, IL4, and IL13. Statistical analysis of cytokine /chemokine profiles in plasma collected pre and 4 hrs post
CpG ODN i.p. injection revealed significant differences (A-R). See Results section for p values. An evident increase in most measured cytokines/
chemokines was observed in both study groups. However, IL1β was detected at very low levels and no differences were observed between
groups (G, P). In addition, IL4 levels were near the limit of detection (data not shown). As expected, reduced cytokine levels were detected in
plasma collected 2 weeks post CpG ODN injection (A-R). See Results section for p values. Data are presented as cytokine responses in plasma
samples collected after the 1st injection from 7 (A-I) and 11 (J-R) month old Tg-control and Tg-CpG ODN mice. No apparent differences in
cytokine levels were observed between the groups at the time of sacrifice (data not shown). Overall, administration of CpG ODN was effective in
inducing immunostimulatory response in the absence of excessive and chronic inflammation in both treatment groups.
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leased in a detectable concentration. There was a signifi-
cant increase in IP10 (two-tailed t test, young, **p = 0.003;
aged, **p = 0.007, Figure 18A, C) and IL10 (young, *p =
0.014; aged, *p = 0.04, Figure 18B, D) brain tissue cytokine
levels 12 hrs post CpG ODN administration in both age
cohorts.
Discussion
Immunomodulation has shown great promise as an AD
therapy, at least in animal models, but major limitations
must be overcome for greater clinical efficacy. Recently,
two large phase III clinical trials using anti-Aβ anti-
bodies, Bapineuzumab and Solunezumab, failed to showA
C
Figure 18 Brain tissue cytokine/chemokine analysis (acute experimen
further characterized in brain tissue samples in 3xTg-AD mice. Unlike in pla
both age cohorts, there were significant increases in IP10 (young, **p = 0.003;
(B, D) brain tissue cytokine levels 12 hrs post CpG ODN administration.overall clinical improvement or any clear disease modify-
ing results [44,45]. We suggest that for immunomodula-
tion to be more successful, the methodology must show
efficacy against all the key pathologies in AD: amyloid pla-
ques, CAA, tau related pathology, and toxic oligomer spe-
cies, with a few or no associated microhemorrhages [2,10].
In our initial studies, we utilized type B CpG ODN to
stimulate innate immunity via TLR9 in the Tg2576 AD
mouse model and showed this to be highly effective at
reducing parenchymal and vascular amyloid burden, cor-
relating with behavioral improvements [9]. However,
there is growing recognition that AD therapy needs to
also address tau related pathology and recent reports
have shown that active and passive immunotherapeuticB
D
t). Immunostimulatory responses to acute CpG ODN treatment were
sma, only 2 cytokines were released at a detectable concentration. In
aged, **p = 0.007) (A, C) and IL10 (young, *p = 0.014; aged, *p = 0.04)
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improve cognition in mouse models of AD [10,46]. Our
current findings demonstrate that stimulation of TLR9
signaling with CpG ODN has beneficial effects on both
plaque and tangle pathologies without toxicity in 3xTg-
AD mice, suggesting that stimulation of innate immunity
has the possible advantage of concurrently addressing
both of these fundamental lesions that characterize AD.
Experiments were designed to test the hypothesis that
CpG ODN treatment can prevent the age-dependent ac-
cumulation of tau and Aβ when started prior to path-
ology development, as well as in established disease.
Peripheral administration of CpG ODN led to a signifi-
cant reduction in cortical and hippocampal amyloid bur-
den and was effective against tau related pathology in
both treatment groups. Immunohistochemistry revealed
a reduction of several tau markers (MC1, PHF1 and
AT8) in the CpG ODN-treated animals, whereas levels
of total tau remained unchanged. These favorable treat-
ment effects of CpG ODN were associated with an im-
provement in cognitive functioning as assessed by radial
arm maze. Cognitive improvements were not con-
founded by any locomotor differences between the Tg
mouse groups. A large body of evidence supports the
concept that the accumulation of aggregated Aβ and tau
species as toxic oligomers, correlates best with cognitive
deficits, making oligomers attractive therapeutic targets
[47,48]. The behavioral rescue observed in animals
treated with CpG ODN was associated with a marked
reduction in Aβ oligomers as documented by Western
blot and ELISA. In addition, treatment with CpG ODN
led to substantial reductions in soluble and total Aβ40
and Aβ42 levels. Levels of CP13 soluble tau levels (S1
fraction) were significantly decreased in mice treated
from 11 to 18 months. A trend for reduced PHF1 react-
ive soluble tau was observed in the same treatment
group. It is likely that the earlier stage CP13 phospho-
tau aggregates were easier to clear than later stage PHF1
assemblies. No alteration in total tau levels was detected
biochemically in our animals treated with CpG ODN,
supporting the safety of this approach. To further con-
firm that this type of immunomodulation did not accel-
erate tau pathology, in contrast to some prior innate
immunity stimulation approaches, additional biochem-
ical analyses were performed. ELISA measurements did
not reveal significant differences between the groups;
hence, no increase in phospho-tau levels was noted in
CpG ODN-treated mice. Our biochemical analyses did
not demonstrate as robust CpG ODN treatment effect
as observed with immunohistochemistry. One potential
explanation for this discrepancy may be that histo-
logical analyses allowed measurement of reduced tau
pathology immunoreactivity in individual cells, whereas
homogenization of the whole brain hemisphere forbiochemical analysis diluted any measurable changes in
specific brain regions. It is possible that part of the tau
pathology reduction effect we observed was secondary
to a reduction in the Aβ pathology. However, since
pathological tau was reduced in the older mouse group
for which treatment began when some tau pathology
was already present, we hypothesize that at least part of
the tau pathology reduction was from a direct effect of
CpG ODN stimulation. To definitively address this ques-
tion, CpG ODN stimulation would need to be tested in a
model with only tau related pathology, without concomi-
tant Aβ pathology; these studies are underway.
Microglial responses, as well as potential signs of cere-
bral toxicity associated with the inflammatory potential
of CpG ODN administration, were assessed at the end
of the study. Microglia can develop a range of pheno-
types broadly corresponding to a spectrum of the M1
state (classical activation) and the M2 state (alternative
activation) [49,50]. The M1 state is associated with the
release of pro-inflammatory cytokines while the M2
phenotype triggers anti-inflammation, promoting tissue
repair [49,50]. The reduction of plaque and tangle path-
ology at the end of the study was paralleled by an overall
reduction in the numbers of activated microglia, as eval-
uated by CD45 (M1 activation marker), CD206 (M2 acti-
vation marker) and CD11b (marker of both M1 and M2
activation) immunoreactivity in CpG ODN-treated ani-
mals. No group differences in the levels of Iba microglio-
sis (marker of both resting and activated microglia) and
CNS astrocytosis were noted. We also did not observe
any T-cell infiltrates in our CpG ODN group. These re-
ductions in microglia markers in CpG ODN-treated an-
imals at the end of long term treatment reflected the
reduction of AD related pathology. We performed add-
itional experiments to assess the effects of TLR9 signal-
ing on the macrophage/microglia activation state and
their ability to promote phagocytosis, on a more acute
basis, in order to assess the mechanisms by which CpG
ODN treatment could lead to AD pathology reduction.
Our short term study was performed in two separate age
cohorts of 3xTg-AD mice. Despite an overall reduction in
CD45, CD11b and CD206 immunoreactivity due to re-
duced plaque load in the CpG ODN-treated mice at the
end of our long term treatment, a transient increase in
CD45, CD11b and CD206 microglial activation was ob-
served 12 hrs after CpG ODN administration in both age
groups. Clearance of AD brain pathology may depend on
bone marrow-derived (BMD) macrophages rather than
resident brain microglia [51-53]. It is likely that TLR9
stimulation with CpG ODN, which does not cross the
BBB, involves targets in the periphery. Direct stimulation
of resident microglia may also be possible to a limited ex-
tent as a result of BBB breakdown in the presence of AD
pathology [54]. Double immunofluorescence using CD45
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BMD peripheral macrophages) revealed increased activa-
tion of microglial cells around amyloid plaques with co-
localization of Aβ and these markers, suggesting that these
cells were actively clearing Aβ deposits [51,55-57]. CD45
and CD206 positive cells were also noted to be increased
in areas with high tau related pathology, but little or no
direct co-localization was found. The mechanisms by
which CpG ODN mediated stimulation of innate immun-
ity could reduce tau pathology are unclear. Tau pathology
has been demonstrated to spread cell to cell via tau oligo-
mers in a prion-like manner [10]. It has also been shown
that tau oligomers, the most toxic forms of aggregated
tau, can activate microglial cells and increase their expres-
sion of scavenger receptor class A [58-60]. It is possible
that TLR9 stimulation via CpG ODN can enhance the
ability of microglia to inhibit this spread of tau related
pathology, suggesting that induction of TLR9 signaling
can be used to successfully target pathological tau in AD
mouse models. Overall, our results suggest that CpG
ODN treatment transiently stimulates a mixed microglia
population with both M1 and M2 activation states to
promote clearance of both Aβ and tau related path-
ology, along with tissue repair. However, long term
treatment is associated with less microglia activation as
the pro-inflammatory stimulus of AD related pathology
is reduced.
In our prior study of CpG ODN treatment in Tg2576
AD model mice we found that the CpG ODN- treated
mice had significantly higher levels of anti-Aβ autoanti-
bodies at the end of the study [9]. We speculated that
this may have been a minor part of the mechanism for
the observed treatment effects. The contribution of this
humoral response was judged to be small as the anti-Aβ
titer, in absolute terms, was very low and it was found
only at the end of treatment, not at earlier time points
[9]. In the current study we did not find evidence that
CpG ODN treatment increased autoantibodies to either
Aβ or tau in 3xTg-AD mice. One possible reason for this
difference is that 3xTg-AD mice have been suggested to
be relatively immunodeficient compared to other AD Tg
models [61]. In one of our previous active immunization
studies where the same protocol was followed concur-
rently in both 3xTg-AD mice and Tg-SwDI AD model
mice, the 3xTg mice had a substantially lower humoral
immune response [19]. Hence, this difference in the
3xTg-AD mice provides a possible explanation for the
discrepancy between our past and current findings.
Another drawback of current vaccination approaches
is limited effectiveness against CAA. Current animal and
human data suggest that CAA is more resistant to clear-
ance compared to parenchymal amyloid and its removal
may be associated with microhemorrhages [62-64]. Add-
itionally, CAA may be involved in the amyloid relatedimaging abnormalities (ARIA) and/or vasogenic edema
of some patients receiving Aβ-immunotherapy, compli-
cations that were not anticipated by numerous studies in
transgenic mouse models [44,65]. Therefore, developing
a therapy that is effective against CAA without inducing
adverse reactions is of critical importance. The present
data document a significant reduction in CAA burden in
the absence of microhemorrhages after CpG ODN admin-
istration. Overall, our findings confirm that administration
of CpG ODN was effective in reducing AD related path-
ology in the absence of encephalitis and without apparent
autoimmune complications, further supporting the safety
of this approach.
There is evidence that neuroinflammation can contrib-
ute to cognitive impairment and play a significant role in
the disease progression [6,11,66]. Conversely, it is becom-
ing increasingly recognized that tightly regulated stimula-
tion of innate immunity processes and specific microglia
activation can be neuroprotective depending on the stimu-
lus and the environment [67]. Experimental evidence sug-
gests that TLR signaling pathways may be involved in the
clearance of Aβ deposits in the brain [12,68]. An in vitro
study has shown that stimulation of microglia with TLR9
agonist CpG ODN attenuated the neurotoxic effect of
Aβ42 oligomers [69]. We and others have demonstrated
that microglial activation associated with TLR9 has bene-
fits in amyloid depositing mice [9,69]. A recent study
using the TLR4 agonist monophosphoryl lipid A (MPL)
gave further evidence that TLRs can be a therapeutic
target in AD [42]. However, only limited studies have
been performed in tau mouse models. Treatment ap-
proaches that reduce amyloid pathology appear to acceler-
ate tau deposition [11-16]. TLR4 ligand (LPS)-induced
MAPT hyperphosphorylation and exacerbation of tau
pathology has been well documented [16,39,40]. Add-
itionally, proinflammatory cytokines, such as IL1β, have
been shown to accelerate formation of NFTs [41]. A
number of studies suggest that inflammation and al-
tered microglial activation play a role in modulating
hyperphosphorylation and aggregation of tau, via acti-
vation of tau specific kinases [16,40]. Conversely, our
data clearly demonstrates that stimulation of innate im-
munity with TLR9 agonist CpG ODN can reduce both
amyloid and tau related pathologies.
To evaluate the pattern of cytokine induction by CpG
ODN we measured cytokine profiles in the plasma both
4 hrs and 2 weeks following injections. CpG ODN ele-
vated the levels of both Th1/Th2 cytokines and chemo-
kines, but the levels were substantially lower than those
generated by LPS in previous studies [42,43]. Import-
antly, production of IL1β, which was shown to exacer-
bate tau pathology, was detected at very low levels, and no
significant changes were observed between our groups
over time [70]. There is also evidence that suggests an
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enhance microglial Aβ degradation, both in vivo and
in vitro, chronic expression of MCP1 has adverse effects
on Aβ deposition [71,72]. Higher peak plasma levels of
MCP1 chemokine were observed 4 hrs after CpG ODN
injection in our study groups; however, the MCP1
levels declined over time. In addition, the levels of
anti-inflammatory cytokine IL10, which induces the
M2-alternative activated phenotype in microglia, were
significantly increased after CpG ODN administration.
IL10 over-expression has been shown to be beneficial
in APP mice [73]. Furthermore, we show that periph-
eral administration of CpG ODN is not associated with
excessive and sustained inflammation, which was con-
firmed by reduced cytokine levels measured 2 weeks
post-injection.
Several reports have suggested a potential benefit of
therapeutically targeting mononuclear cells to reduce
AD related pathology [2,52]. Microglia lose their Aβ
clearing capabilities as AD progresses [51,74,75]. Senes-
cence of microglia function has been suggested to play a
fundamental role in both AD and other neurodegenera-
tive diseases [28,76]. Prior studies have also shown that
microglia become significantly more efficient at Aβ up-
take and degradation when stimulated with TLR agonists
in vitro [77,78]. It has been reported that activation of
microglia with TLR agonists can induce acidification of
lysosomes, allowing efficient degradation of Aβ [75].
However, the relationship to tau pathology has yet to be
studied. We hypothesize that our approach of immuno-
modulation can boost peripheral macrophages/microglia
to specifically clear both species, enhancing pathological
Aβ and tau trafficking to endosomes/lysosomes leading
to more efficient degradation.
Conclusions
The present study represents the first in vivo evidence
that stimulation of TLR9 signaling with CpG ODN re-
duces behavioral deficits and is effective against all the
major pathological hallmarks of AD in the absence of
apparent toxicity. In addition, these beneficial effects of
CpG ODN in 3xTg-AD mice were observed when treat-
ment was initiated early in the course of disease as well
once more advanced disease had set in. This suggests
that the age related defects in immune cell function may
be reversed by limited innate immunity stimulation via
TLR9, even at later stages of disease. Any future clinical
use of CpG ODN for AD would likely target a popula-
tion of whom a substantial proportion will already have
extensive pathology. Further studies using a well charac-
terized non-human primate model of sporadic CAA,
aged squirrel monkeys, are ongoing in our group and
will provide essential preclinical evidence for CpG ODN
as a disease modifying drug for AD in the setting ofestablished pathology. Several CpG DNA drugs have
shown favorable safety profiles in humans and have been
tested in numerous clinical trials as anti-tumor, anti-
microbial agents and as adjuvants in vaccines [8]. Our
data are suggestive that stimulation of innate immunity
has the potential to safely ameliorate all features of AD.Competing interests
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